Submit Manuscript

International Journal of Pharmacology

Year: 2019 | Volume: 15 | Issue: 6 | Page No.: 731-737
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 186

Authors

Usama Ahmed Fahmy

Usama Ahmed Fahmy

Osama Abdelhakim Aly Ahmed

Osama Abdelhakim Aly Ahmed

Nabil Abdulhafiz Alhakamy

Keywords

Research Article

Augmentation of Alendronate Cytotoxicity Against Breast Cancer Cells by Complexation with Trans-activating Regulatory Protein

Usama Ahmed Fahmy Usama Ahmed Fahmy's LiveDNA, Osama Abdelhakim Aly Ahmed Osama Abdelhakim Aly Ahmed's LiveDNA and Nabil Abdulhafiz Alhakamy
Background and Objective: Alendronate sodium (ALS) is a member of the class bisphosphonates used to treat osteoporosis. Recent reports suggested that ALS may induce cell death and inhibit the proliferation of estrogen-sensitive MCF-7 breast cancer cells. The aim of this work was the combination of ALS and trans-activating regulatory protein (TAT) loaded nanostructured lipid carriers (NLCs) to potentiate ALS cytotoxicity against MCF-7 breast cancer cells. Materials and Methods: The ALS and TAT were prepared and loaded in NLCs. The formed NLCs were characterized for entrapment efficiency (%) (EE %), particle size and zeta potential. Cell viability was also carried out for the prepared NLCs. Results: The results revealed that the prepared NLCs were spherical, with particle sizes of 285.2±14.1 nm and polydispersity index of 0.51. Zeta potential of ALS-TAT-NLCs was +21.1±3.4 mV. The ALS EE percentage of the prepared NLCs was 12.2±1.1%. At concentration of 10 μg mL–1, the investigated formulations showed cell survival percentage of 6.86, 20.34, 97.53 and 91.55% for ALS-TAT NLCs, raw ALS, raw TAT and plain NLCs, respectively. The IC50 values for the treatments were estimated as follows: ALS-TAT NLCs, 1.98±0.17 μg mL–1, raw ALS, 2.77±0.36 μg mL–1, raw TAT, 1066.67±21.22 μg mL–1 and plain NLCs, 10816.2±112.32 μg mL–1. Conclusion: The combination of ALS with TAT protein loaded NLCs offered a dual mechanism of ALS activity potentiation and a promising candidate for breast cancer therapy.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *